Gel indicated to prevent and treat cervical lesions* caused by HPV.

*Low-grade cervical lesions (ASCUS/LSIL)

What is it?

Papilocare® vaginal gel is the first treatment that has been scientifically demonstrated to have a very high success rate in eliminating not only the Human Papiloma Virus (HPV), but also the initial precancerous lesions of the cervix.

It was specifically designed with this goal in mind and has a patented formula based on seven hormone-free ingredients, making it a safe treatment, highly tolerable and highly recommended by specialists in gynaecology and women’s healthcare.

How does it work?

HPV is the most common sexually transmitted virus worldwide, which in most cases, is spontaneously cleared by the body in an average of two years. However, sometimes the virus can evade it and remain in the body, which is the main risk factor for developing lesions that could develop into a bigger threat over time as long as they are not detected and treated properly.

¿Cuándo debo utilizarlo?

When should I use it?

Its use will prove beneficial if you are at least 18 years old, have had sexual intercourse and have received a diagnosis of HPV infection from a gynecologist or medical specialist.

If you meet these conditions, Papilocare® vaginal gel will help you prevent the risk of lesions caused by the virus by re-epithelializing the transformation zone of the cervix, normalizing the intraepithelial lesions caused by it, eliminating vaginal dryness, re-epithelializing the cervical-vaginal mucosa, rebalancing the vaginal microbiota and improving vaginal health in general.

In any given situation, always consult your medical specialist before use.

Papilocare® vaginal gel is specifically designed to activate the two modifiable factors that can influence HPV’s persistence or eradication. In addition, some of its ingredients are encapsulated in niosomes and phytosomes, a cutting-edge technology that offers greater efficacy by favouring their action in the basal layers of the epithelium, as well as improving the ingredients.

A unique formula on the market

Papilocare® vaginal gel acts by forming a film on the cervical mucosa, creating a defensive barrier to prevent the risk of HPV integration and quickly reduces the discomfort caused by the infection, accelerating the natural healing process for scars.

These effects are possible thanks to its innovative technology and its unique formula composed of seven components, including Coriolus versicolor extract, a fungus widely used in traditional Chinese medicine, and Bioecolia®, a prebiotic which promotes the growth of beneficial bacteria such as Lactobacillus crispatus

Furthermore, its formula includes hyaluronic acid, beta-glucan, centella asiatica, neem extract and aloe vera extract. Through this powerful combination, the vaginal gel fulfills many roles:

Re-epithelializing

Prebiotic: Promotes the growth of beneficial bacterial microbiota and rebalances the microbiota in the cervix-vaginal area

Moisturizing: Maintains the correct elasticity of internal tissues

Antioxidant: Maintains the skin and mucous membrane’s natural structure and functionality, as well as improving the barrier function of the epithelium

Repairs: the injured mucosa.

Emollient: Promotes the natural healing process of scars

Scientific Evidence

The efficacy of Papilocare® vaginal gel has been studied and demonstrated in several international clinical trials, with more than 600 patients participating. Among all of them, the PALOMA clinical trial stands out, its results have been recently published in the American scientific journal “Journal of Lower Genital Tract Diseases”.

Furthermore, the PAPILOBS observational study has just finished, as well as five other independent studies carried out by public hospitals in Spain and Italy

The results obtained were similar in all of them, among the achievements of the treatment, the following stand out:

 Normalization of low-grade lesions of the cervix in 88% of patients   infected with high-risk HPV after six months of treatment,   compared to 56% of patients who were not treated

 Negative results on high-risk HPV test after treatment in 63% of   patients who followed the Papilocare® vaginal gel regimen,   compared to 40% of the control group

Doctor Javier Cortés:

“The results of PALOMA clinical trial allow to say firmly  that we have now something that we didn’t have before  a safe and reliable treatment against HPV with optimal results “.

Doctor Luis Serrano:

“Papilocare® is an important advance for women who are HPV positive, a field  which doesn´t have many therapeutic solutions “.

How to use it?

A complete treatment, which guarantees the results obtained in the clinical studies carried out, has a duration of six months.

It is recommended to start the administration of the vaginal gel just after menstruation, following the guidelines

 First month: Daily application for 21 consecutive days or until the first day of menstruation, stop its use and rest while bleeding.

 Following months: One application every other day for 21 days or until the first day of menstruation and rest during bleeding.

    Things to keep in mind:

  • The recommended dose for each application is a single-dose cannula or 3ml with the reusable applicator
  • The treatment must be stopped while menstruating
  • Papilocare® vaginal gel should preferably be used before bedtime.
  • It is compatible with preservatives, meaning there’s no risk of using both simultaneously.

Apply the product

  • Lie on your back and insert the reusable cannula or applicator into your vagina, pressing the container to release the content inside
 
  • If individual cannulas are used, it is important to remove them from the vagina while squeezing to avoid suctioning back the product already administered, discard them after use.

You may also be interested in

PAPILOCARE®

External Gel

PAPILOCARE®

Inmunocaps